|
N-[2-[(4-hydroxyphenyl)amino]-3-pyridinyl]-4-methoxybenzenesulfonamide |
|---|---|
| Trade Name | |
| Orphan Indication | Neuroblastoma |
| USA Market Approval | USA |
| USA Designation Date | 2004-09-30 00:00:00 |
| Sponsor | AbbVie, Inc.;1 N. Waukegan Road;North Chicago, Illinois, 60064 |
Related Access Program
South Plains Oncology Consortium – Recurrent Neuroblastoma
Catalyst Pharmaceuticals, Inc. – Downbeat Nystagmus
South Plains Oncology Consortium – Neuroblastoma
British Columbia Cancer Agency – Neuroblastoma
South Plains Oncology Consortium – Neuroblastoma
Children’s Hospital of Philadelphia – Neuroblastoma
University of California, San Francisco – Neuroblastoma
Jubilant DraxImage Inc. – Neuroblastoma
Children’s Hospital Medical Center, Cincinnati – Neuroblastoma
Apeiron Biologics AG – Neuroblastoma
